Cargando…

Improved glycemic control and reduced bodyweight with exenatide: A double‐blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

Aims/Introduction: To evaluate the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist, exenatide, in Japanese patients with type 2 diabetes mellitus suboptimally controlled despite therapeutic doses of a sulfonylurea alone or combined with a biguanide or thiazolidinedione. Material...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadowaki, Takashi, Namba, Mitsuyoshi, Imaoka, Takeshi, Yamamura, Ayuko, Goto, Wakana, Boardman, Marilyn K., Sowa, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014921/ https://www.ncbi.nlm.nih.gov/pubmed/24843486 http://dx.doi.org/10.1111/j.2040-1124.2010.00084.x

Ejemplares similares

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2011)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell, Leigh, et al.
Publicado: (2013)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
por: Taylor, Kristin, et al.
Publicado: (2011)

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
por: Pereira, Maria J., et al.
Publicado: (2018)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Effect of mild exercise on glycemic and bodyweight control in Japanese type 2 diabetes patients: A retrospective analysis
por: Nakanishi, Shuhei, et al.
Publicado: (2018)

Frequency and predictors of suboptimal glycemic control in an African diabetic population
por: Kibirige, Davis, et al.
Publicado: (2017)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
por: Wysham, Carol H, et al.
Publicado: (2020)

Characteristics of Children with Type 1 Diabetes and Persistent Suboptimal Glycemic Control
por: Kim, Hyuntae, et al.
Publicado: (2012)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

Comparison of three α‐glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes
por: Sugihara, Hitoshi, et al.
Publicado: (2013)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes
por: Htike, Zin Z., et al.
Publicado: (2012)

Low-carbohydrate diet in type 2 diabetes: stable improvement of bodyweight and glycemic control during 44 months follow-up
por: Nielsen, Jörgen V, et al.
Publicado: (2008)

Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up
por: Nielsen, Jørgen Vesti, et al.
Publicado: (2006)

The Rapid Changes in Bodyweight and Glycemic Control Are Determined by Pre-status After Bariatric Surgery in Both Genders in Young Chinese Individuals
por: Wen, Song, et al.
Publicado: (2023)

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
por: Russell-Jones, David, et al.
Publicado: (2012)

Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system
por: Li, Yang, et al.
Publicado: (2020)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study
por: Inaishi, Jun, et al.
Publicado: (2022)

Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial
por: Yin, Ting-Ting, et al.
Publicado: (2018)

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
por: Klausen, Mette Kruse, et al.
Publicado: (2022)

Lifestyle changes as a result of COVID‐19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency
por: Tanaka, Nagaaki, et al.
Publicado: (2021)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
por: Gallwitz, Baptist, et al.
Publicado: (2011)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

The effect of bodyweight exercise on 24-h glycemic responses determined by continuous glucose monitoring in healthy inactive adults: a randomized crossover study
por: Babir, Fiona J., et al.
Publicado: (2023)

Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study
por: Jude, Edward B., et al.
Publicado: (2019)

Neonatal–Maternal Bodyweight Ratio at Birth: An Indicator for First-Week Survival Prognosis in Canine Newborns
por: Alonge, Salvatore, et al.
Publicado: (2023)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders, William B, et al.
Publicado: (2016)

Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
por: Di Pierro, Francesco, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_llao14s51tc3jo8cs2561lhgg1